Abstract
Insulin‐like growth factor (IGF)‐I has cancer promoting activities. However, the hypothesis that circulating IGF‐I concentration is related to risk of lymphoma overall or its subtypes has not been examined prospectively. IGF‐I concentration was measured in pre‐diagnostic plasma samples from a nested case–control study of 1,072 cases of lymphoid malignancies and 1,072 individually matched controls from the European Prospective Investigation into Cancer and Nutrition. Odds ratios (ORs) and confidence intervals (CIs) for lymphoma were calculated using conditional logistic regression. IGF‐I concentration was not associated with overall lymphoma risk (multivariable‐adjusted OR for highest versus lowest third = 0.77 [95% CI = 0.57–1.03], p trend = 0.06). There was no statistical evidence of heterogeneity in this association with IGF‐I by sex, age at blood collection, time between blood collection and diagnosis, age at diagnosis, or body mass index (p heterogeneity for all ≥ 0.05). There were no associations between IGF‐I concentration and risk for specific BCL subtypes, T‐cell lymphoma or Hodgkin lymphoma, although number of cases were small. In this European population, IGF‐I concentration was not associated with risk of overall lymphoma. This study provides the first prospective evidence on circulating IGF‐I concentrations and risk of lymphoma. Further prospective data are required to examine associations of IGF‐I concentrations with lymphoma subtypes.
Highlights
These authors arranged a NESTED case–control study with participants from the European Prospective Investigation into Cancer and Nutrition (EPIC). They tested for insulin-like growth factor I (IGF-I) in pre-diagnosis samples and found no association between the factor and overall lymphoma risk, nor with any subtype, the number of cases was small for each subptyrpoes,peacntdivfeurdtahtear asrteudrieeqsuairreednteocesxsaamryin.e associations of Insulin-like growth factor (IGF)-I concentrations with lymphoma subtypes
BMI, and geometric mean circulating concentrations of plasma IGF-I of case patients and control participants are shown in Supporting Information Table 1
There was no evidence of heterogeneity in the association of IGF-I and risk of overall lymphoma (Table 3) by sex, age at blood collection, time between blood collection and diagnosis, age at diagnosis, or BMI. In this large European prospective study, plasma concentration of IGF-I was not associated with overall risk for lymphoma
Summary
IGF-I concentration was measured in pre-diagnostic plasma samples from a nested case–control study of 1,072 cases of lymphoid malignancies and 1,072 individually matched controls from the European Prospective Investigation into Cancer and Nutrition. There were no associations between IGF-I concentration and risk for specific BCL subtypes, T-cell lymphoma or Hodgkin lymphoma, number of cases were small. These authors arranged a NESTED case–control study with participants from the European Prospective Investigation into Cancer and Nutrition (EPIC). They tested for IGF-I in pre-diagnosis samples and found no association between the factor and overall lymphoma risk, nor with any subtype, the number of cases was small for each subptyrpoes,peacntdivfeurdtahtear asrteudrieeqsuairreednteocesxsaamryin.e associations of IGF-I concentrations with lymphoma subtypes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
